BGSI vs COLL vs MNRO vs DRVN vs MUSA

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus -6. 4% for Monro, Inc. (MNRO). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 20. 6x trailing P/E (4. 8x forward), making it the more compelling value choice. Analysts rate Boyd Group Services Inc. (BGSI) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 20. 6x versus Boyd Group Services Inc. at 134. 5x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 4. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Collegium Pharmaceutical, Inc. wins at 0. 27x versus Murphy USA Inc. 's 1. 39x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Murphy USA Inc.

(MUSA) delivered a total return of +329. 7%, compared to -66. 8% for Monro, Inc. (MNRO). Over 10 years, the gap is even starker: MUSA returned +788. 7% versus MNRO's -63. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Murphy USA Inc.

(MUSA) is the lower-risk stock at -0. 23β versus Monro, Inc. 's 1. 57β — meaning MNRO is approximately -778% more volatile than MUSA relative to the S&P 500. On balance sheet safety, Monro, Inc. (MNRO) carries a lower debt/equity ratio of 85% versus 7% for Driven Brands Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus -6. 4% for Monro, Inc. (MNRO). On earnings-per-share growth, the picture is similar: Driven Brands Holdings Inc. grew EPS 59. 8% year-over-year, compared to -119. 3% for Monro, Inc.. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus -12. 5% for Driven Brands Holdings Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BGSI leads at 92. 2% versus -6. 0% for DRVN. At the gross margin level — before operating expenses — COLL leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Collegium Pharmaceutical, Inc. (COLL) is the more undervalued stock at a PEG of 0. 27x versus Murphy USA Inc. 's 1. 39x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Collegium Pharmaceutical, Inc. (COLL) trades at 4. 8x forward P/E versus 30. 0x for Monro, Inc. — 25. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MNRO: 147. 5% to $40. 00.

In this comparison, MNRO (6.

9% yield), BGSI (0. 4% yield), MUSA (0. 4% yield) pay a dividend. COLL, DRVN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Murphy USA Inc.

(MUSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 23), +788. 7% 10Y return). Monro, Inc. (MNRO) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MUSA: +788. 7%, MNRO: -63. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGSI (Consumer Cyclical) and COLL (Healthcare) and MNRO (Consumer Cyclical) and DRVN (Consumer Cyclical) and MUSA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BGSI is a small-cap quality compounder stock; COLL is a small-cap high-growth stock; MNRO is a small-cap income-oriented stock; DRVN is a small-cap quality compounder stock; MUSA is a mid-cap quality compounder stock. MNRO pays a dividend while BGSI, COLL, DRVN, MUSA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.